Jorge Carlos Garces1, Sixto Giusti2, Catherine Staffeld-Coit3, Humberto Bohorquez1, Ari J Cohen1, George E Loss1. 1. Multi-Organ Transplant Institute, Ochsner Clinic Foundation, New Orleans, LA ; The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA. 2. Multi-Organ Transplant Institute, Ochsner Clinic Foundation, New Orleans, LA ; Department of Nephrology, Ochsner Clinic Foundation, New Orleans, LA. 3. The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA ; Department of Nephrology, Ochsner Clinic Foundation, New Orleans, LA.
Abstract
BACKGROUND: Chronic antibody injury is a serious threat to allograft outcomes and is therefore the center of active research. In the continuum of allograft rejection, the development of antibodies plays a critical role. In recent years, an increased recognition of molecular and histologic changes has provided a better understanding of antibody-mediated rejection (AMR), as well as potential therapeutic interventions. However, several pathways are still unknown, which accounts for the lack of efficacy of some of the currently available agents that are used to treat rejection. METHODS: We review the current diagnostic criteria for AMR; AMR paradigms; and desensitization, treatment, and prevention strategies. RESULTS: Chronic antibody-mediated endothelial injury results in transplant glomerulopathy, manifested as glomerular basement membrane duplication, double contouring, or splitting. Clinical manifestations of AMR include proteinuria and a rise in serum creatinine. Current strategies for the treatment of AMR include antibody depletion with plasmapheresis (PLEX), immunoadsorption (IA), immunomodulation with intravenous immunoglobulin (IVIG), and T cell- or B cell-depleting agents. Some treatment benefits have been found in using PLEX and IA, and some small nonrandomized trials have identified some benefits in using rituximab and the proteasome inhibitor-based therapy bortezomib. More recent histologic follow-ups of patients treated with bortezomib have not shown significant benefits in terms of allograft outcomes. Furthermore, no specific treatment approaches have been approved by the US Food and Drug Administration. Other agents used for more difficult rejections include bortezomib and eculizumab (an anti-C5 monoclonal antibody). CONCLUSION: AMR is a fascinating field with ample opportunities for research and progress in the future. Despite the use of advanced techniques for the detection of human leukocyte antigen (HLA) or non-HLA donor-specific antibodies, alloimmune response remains an important barrier for successful long-term allograft function. Treatment of AMR with currently available therapies has produced a variety of results, some of them suboptimal, precluding the development of standardized protocols. New therapies are promising, but randomized controlled trials are needed to find surrogate markers and improve the efficacy of therapy.
BACKGROUND:Chronic antibody injury is a serious threat to allograft outcomes and is therefore the center of active research. In the continuum of allograft rejection, the development of antibodies plays a critical role. In recent years, an increased recognition of molecular and histologic changes has provided a better understanding of antibody-mediated rejection (AMR), as well as potential therapeutic interventions. However, several pathways are still unknown, which accounts for the lack of efficacy of some of the currently available agents that are used to treat rejection. METHODS: We review the current diagnostic criteria for AMR; AMR paradigms; and desensitization, treatment, and prevention strategies. RESULTS: Chronic antibody-mediated endothelial injury results in transplant glomerulopathy, manifested as glomerular basement membrane duplication, double contouring, or splitting. Clinical manifestations of AMR include proteinuria and a rise in serum creatinine. Current strategies for the treatment of AMR include antibody depletion with plasmapheresis (PLEX), immunoadsorption (IA), immunomodulation with intravenous immunoglobulin (IVIG), and T cell- or B cell-depleting agents. Some treatment benefits have been found in using PLEX and IA, and some small nonrandomized trials have identified some benefits in using rituximab and the proteasome inhibitor-based therapy bortezomib. More recent histologic follow-ups of patients treated with bortezomib have not shown significant benefits in terms of allograft outcomes. Furthermore, no specific treatment approaches have been approved by the US Food and Drug Administration. Other agents used for more difficult rejections include bortezomib and eculizumab (an anti-C5 monoclonal antibody). CONCLUSION: AMR is a fascinating field with ample opportunities for research and progress in the future. Despite the use of advanced techniques for the detection of human leukocyte antigen (HLA) or non-HLA donor-specific antibodies, alloimmune response remains an important barrier for successful long-term allograft function. Treatment of AMR with currently available therapies has produced a variety of results, some of them suboptimal, precluding the development of standardized protocols. New therapies are promising, but randomized controlled trials are needed to find surrogate markers and improve the efficacy of therapy.
Authors: Michelle Willicombe; Candice Roufosse; Paul Brookes; Jack W Galliford; Adam G McLean; Anthony Dorling; Anthony N Warrens; Terry H Cook; Tom D Cairns; David Taube Journal: Transplantation Date: 2011-07-27 Impact factor: 4.939
Authors: Banu Sis; Gian S Jhangri; Sakarn Bunnag; Kara Allanach; Bruce Kaplan; Philip F Halloran Journal: Am J Transplant Date: 2009-07-22 Impact factor: 8.086
Authors: C Wiebe; I W Gibson; T D Blydt-Hansen; M Karpinski; J Ho; L J Storsley; A Goldberg; P E Birk; D N Rush; P W Nickerson Journal: Am J Transplant Date: 2012-03-19 Impact factor: 8.086
Authors: H E Feucht; H Schneeberger; G Hillebrand; K Burkhardt; M Weiss; G Riethmüller; W Land; E Albert Journal: Kidney Int Date: 1993-06 Impact factor: 10.612
Authors: G Einecke; B Sis; J Reeve; M Mengel; P M Campbell; L G Hidalgo; B Kaplan; P F Halloran Journal: Am J Transplant Date: 2009-11 Impact factor: 8.086
Authors: Bassam G Abu Jawdeh; Madison C Cuffy; Rita R Alloway; Adele Rike Shields; E Steve Woodle Journal: Clin Transplant Date: 2014-03-12 Impact factor: 2.863
Authors: William R Mulley; Fiona J Hudson; Brian D Tait; Alison M Skene; John P Dowling; Peter G Kerr; John Kanellis Journal: Transplantation Date: 2009-01-27 Impact factor: 4.939
Authors: E Steve Woodle; Simon Tremblay; Paul Brailey; Alin Girnita; Rita R Alloway; Bruce Aronow; Nupur Dasgupta; Frederic Ebstein; Peter-Michael Kloetzel; Min Jae Lee; Kyung B Kim; Harinder Singh; James J Driscoll Journal: Am J Transplant Date: 2019-12-11 Impact factor: 8.086
Authors: Manu Chhabra; Jawaher Alsughayyir; M Saeed Qureshi; Mekhola Mallik; Jason M Ali; Ivonne Gamper; Ellen L Moseley; Sarah Peacock; Vasilis Kosmoliaptsis; Martin J Goddard; Michelle A Linterman; Reza Motallebzadeh; Gavin J Pettigrew Journal: Front Immunol Date: 2019-01-23 Impact factor: 7.561
Authors: John P Maufort; Jacqueline S Israel; Matthew E Brown; Steve J Kempton; Nicholas J Albano; Weifeng Zeng; Laurel E Kelnhofer; Matthew R Reynolds; Elizabeth S Perrin; Ruston J Sanchez; Igor I Sluvkin; James A Thomson; Samuel O Poore Journal: J Am Heart Assoc Date: 2019-07-17 Impact factor: 5.501